GO:0031436 BRCA1-BARD1 complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031436 (BRCA1-BARD1 complex) is a cellular_component term describing a heterodimeric complex of BRCA1 and BARD1 that possesses ubiquitin ligase activity and functions in genome maintenance.
• The complex is a central tumor suppressor module whose loss or dysfunction is linked to hereditary breast and ovarian cancer and other malignancies.
• BRCA1-BARD1 promotes homologous recombination by enabling DNA end resection, RAD51-mediated DNA pairing, and protection of resected DNA ends.
• The complex is recruited to damaged chromatin through structural determinants that read histone and DNA damage marks.
• BRCA1-BARD1 also participates in resolution of joint DNA molecules together with BLM, and recognizes pre-ribosomal RNA to facilitate homologous recombination.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are essential for dissecting BRCA1-BARD1 function in DNA repair and tumor suppression.
Description
The BRCA1-BARD1 complex (GO:0031436) is a heterodimeric cellular component composed of the BRCA1 and BARD1 proteins, which together form a functional ubiquitin E3 ligase and act as a critical tumor suppressor module. QuickGO defines this term as a heterodimeric complex comprising BRCA1 and BARD1, which possesses ubiquitin ligase activity and is involved in genome maintenance, possibly by functioning in surveillance for DNA damage. Because BRCA1 and BARD1 are obligate partners, the complex rather than either monomer is generally considered the biologically relevant unit in DNA repair and replication. Researchers study GO:0031436 because it sits at the intersection of genome stability, replication, and cancer predisposition. The complex promotes homologous recombination (HR) by supporting DNA end resection, RAD51-mediated homologous DNA pairing, and protection of resected DNA ends. It is recruited to damaged chromatin through structural determinants that recognize damage-associated marks, and it coordinates with other repair factors such as BLM to resolve joint DNA molecules. The complex has also been implicated in recognizing pre-ribosomal RNA to facilitate homologous recombination. From a translational perspective, understanding the BRCA1-BARD1 complex is essential for interpreting cancer risk variants, predicting responses to DNA-damaging agents and PARP inhibitors, and designing CRISPR-based models that test causality of candidate variants. This article summarizes the authoritative GO definition, the complex's composition and assembly, its molecular mechanism, its roles in disease, and the experimental methods used to study it.
BRCA1-BARD1 complex At A Glance
| GO ID | GO:0031436 |
|---|---|
| GO term | BRCA1-BARD1 complex |
| Ontology | cellular_component |
| Synonym | None listed in QuickGO |
| Major function | Ubiquitin ligase activity and genome maintenance, including DNA damage surveillance and homologous recombination |
| Complex type | Heterodimer of BRCA1 and BARD1 |
| Associated processes | DNA repair, DNA replication, homologous recombination, DNA end resection, RAD51-mediated DNA pairing |
| Disease relevance | Hereditary breast and ovarian cancer and other cancers associated with BRCA1/BARD1 dysfunction |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, structural biology, and repair assays |
What Is GO:0031436?
GO:0031436 (BRCA1-BARD1 complex) is a cellular_component term that describes a heterodimeric protein complex formed by BRCA1 and BARD1. According to the QuickGO definition, this complex possesses ubiquitin ligase activity and is involved in genome maintenance, possibly by functioning in surveillance for DNA damage. The complex is therefore not merely a physical association of two proteins but a functional enzymatic and scaffolding unit that contributes to DNA repair, replication, and genome stability.
Why Is BRCA1-BARD1 complex Important in Cell Biology?
The BRCA1-BARD1 complex is important because it is a principal tumor suppressor module that maintains genome integrity through ubiquitin ligase activity and homologous recombination. Its dysfunction is directly linked to hereditary cancer predisposition, and its activity influences sensitivity to DNA-damaging chemotherapy and PARP inhibitors. Studying GO:0031436 therefore informs cancer risk assessment, mechanism-based therapy, and the functional interpretation of BRCA1 and BARD1 variants.
• Central tumor suppressor complex in hereditary breast and ovarian cancer.
• Possesses ubiquitin E3 ligase activity that contributes to genome maintenance.
• Promotes homologous recombination by enabling DNA end resection.
• Stimulates RAD51-mediated homologous DNA pairing.
• Protects resected DNA ends from inappropriate degradation.
• Recruited to damaged chromatin via structural determinants.
• Coordinates with BLM in joint DNA molecule resolution.
• Recognizes pre-ribosomal RNA to facilitate homologous recombination.
• Influences response to PARP inhibitors and DNA-damaging agents.
• Provides a model system for CRISPR-based functional genomics of DNA repair.
Structure and Composition of BRCA1-BARD1 complex
Heterodimerization of BRCA1 and BARD1
In simple terms: BRCA1 and BARD1 stick together to form one working unit.
The BRCA1-BARD1 complex is a heterodimer in which BRCA1 and BARD1 associate through their N-terminal RING domains to form a functional ubiquitin E3 ligase. This obligate partnership is required for the complex's stability and enzymatic activity, and the heterodimer is considered the biologically relevant tumor suppressor unit.
Recruitment to damaged chromatin
In simple terms: The complex has a docking system that helps it find damaged DNA.
Structural studies have revealed how the BRCA1-BARD1 complex is recruited to damaged chromatin, including determinants that recognize damage-associated chromatin marks. This recruitment is a prerequisite for the complex to act locally at DNA lesions and to initiate downstream repair events.
DNA end resection and protection
In simple terms: The complex helps create and then shield the single-stranded DNA tails needed for repair.
BRCA1-BARD1 promotes DNA end resection during homologous recombination and also protects resected DNA ends from excessive degradation. These dual activities help channel repair toward homologous recombination and away from error-prone pathways.
RAD51-mediated DNA pairing
In simple terms: The complex helps the RAD51 protein find and pair matching DNA sequences.
The BRCA1-BARD1 complex promotes RAD51-mediated homologous DNA pairing, a key step in homologous recombination. This function links the complex directly to the strand invasion and template search steps of HR.
Coordination with BLM and joint molecule resolution
In simple terms: The complex works with other enzymes to untangle DNA intermediates.
BRCA1-BARD1 coordinates with BLM in complementary mechanisms of joint DNA molecule resolution. This coordination helps complete recombination and prevents the accumulation of unresolved DNA intermediates.
Recognition of pre-ribosomal RNA
In simple terms: The complex can also bind a type of RNA to help with recombination.
The BRCA1-BARD1 complex recognizes pre-ribosomal RNA to facilitate homologous recombination. This observation expands the complex's functional repertoire beyond DNA-only transactions and links it to RNA-associated repair contexts.
Key Genes Involved in GO:0031436 BRCA1-BARD1 complex
The BRCA1-BARD1 complex is defined by its two core subunits and is functionally connected to a network of DNA repair and replication genes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BRCA1 | Core subunit of the BRCA1-BARD1 heterodimer; tumor suppressor | Central to hereditary breast and ovarian cancer and HR research |
| BARD1 | Core subunit of the BRCA1-BARD1 heterodimer; required for complex stability and ligase activity | Frequently studied alongside BRCA1 in cancer predisposition and repair assays |
| RAD51 | Mediates homologous DNA pairing downstream of BRCA1-BARD1 | Readout for HR proficiency in BRCA1-BARD1 models |
| BLM | Coordinates with BRCA1-BARD1 in joint DNA molecule resolution | Used to study recombination intermediate processing |
| BARD1 RING domain | Mediates heterodimerization with BRCA1 | Target for structural and mutational studies |
| BRCA1 RING domain | Mediates heterodimerization with BARD1 and E3 ligase activity | Hotspot for cancer-associated variants |
| BRCA1 C-terminal region | Contributes to recruitment and repair functions | Studied in chromatin recruitment assays |
| BARD1 BRCT domain | Supports complex function and interactions | Investigated in structural and functional studies |
| BRCA1 BRCT domain | Supports recruitment and repair functions | Commonly mutated in cancer and studied in CRISPR models |
| RAD51 paralogs | Assist RAD51-mediated pairing | Used to dissect HR pathway dependencies |
| Pre-ribosomal RNA | Ligand recognized by BRCA1-BARD1 to facilitate HR | Studied in RNA-associated recombination contexts |
| Ubiquitin | Substrate tag linked to BRCA1-BARD1 E3 ligase activity | Used to assay ligase function |
| Histone marks | Chromatin features recognized during recruitment | Used in chromatin recruitment studies |
| DNA damage sensors | Upstream signals that recruit the complex | Studied in damage response assays |
| Cell cycle regulators | Influence when the complex acts | Used to contextualize HR timing |
| PARP | Therapeutic target linked to BRCA1-BARD1 deficiency | Used in synthetic lethality studies |
| Replication machinery | Coordinates with BRCA1-BARD1 during replication | Studied in replication stress models |
How Is BRCA1-BARD1 complex Regulated?
The BRCA1-BARD1 complex is regulated at multiple levels, including its obligate heterodimerization, recruitment to damaged chromatin, and coordination with other repair factors. Its recruitment to damaged chromatin is mediated by structural determinants that recognize damage-associated marks, and its activity is coordinated with BLM during joint DNA molecule resolution. The complex also functions in the context of DNA replication and the DNA damage response, which together determine when and where it acts.
BRCA1-BARD1 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BRCA1 | Hereditary breast and ovarian cancer; HR deficiency | CRISPR knockout and point-mutation cell models |
| BARD1 | Cancer predisposition linked to complex dysfunction | Knockout and knock-in models of BARD1 variants |
| RAD51 | HR proficiency and therapy response | Reporter assays and RAD51 foci models |
| BLM | Recombination intermediate processing and genome stability | Co-knockout and resolution assays |
| BRCA1-BARD1 complex | Genome instability and DNA damage surveillance | Isogenic CRISPR models with repair readouts |
Hereditary breast and ovarian cancer
Dysfunction of the BRCA1-BARD1 complex is strongly associated with hereditary breast and ovarian cancer, and the complex is a central tumor suppressor module in these malignancies. Loss of complex activity impairs homologous recombination and genome maintenance, contributing to cancer predisposition.
Homologous recombination deficiency and therapy response
Because BRCA1-BARD1 promotes DNA end resection, RAD51-mediated pairing, and protection of resected ends, its deficiency causes homologous recombination defects that can be exploited therapeutically with DNA-damaging agents and PARP inhibitors. Functional status of the complex is therefore relevant to treatment selection.
Genome instability and DNA repair disorders
The complex's roles in DNA repair, replication, and joint molecule resolution mean that its dysfunction can lead to genome instability. Coordination with BLM is particularly important for resolving recombination intermediates and avoiding deleterious DNA structures.
RNA-associated repair contexts
Recognition of pre-ribosomal RNA by BRCA1-BARD1 to facilitate homologous recombination suggests that the complex may be relevant in disease contexts where RNA-associated repair contributes to genome stability. This emerging area may inform future mechanistic and therapeutic studies.
From BRCA1-BARD1 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of BRCA1-BARD1 impair homologous recombination? | CRISPR knockout of BRCA1 or BARD1 with HR reporter assays |
| Which residues are required for DNA end resection? | Point-mutation knock-in of BRCA1 or BARD1 |
| How does the complex recognize damaged chromatin? | Tagged knock-in and chromatin recruitment imaging |
| Can a candidate variant restore complex function? | Knock-in of patient variants followed by repair assays |
| Does overexpression alter DNA repair balance? | Overexpression models with repair and survival readouts |
| How does the complex coordinate with BLM? | Co-knockout or double-mutant models with joint molecule assays |
How to Study the BRCA1-BARD1 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HR reporter assay | Homologous recombination efficiency | Testing BRCA1-BARD1 loss or variants |
| DNA end resection assay | Resection tract formation | Dissecting resection promotion and protection |
| RAD51 foci imaging | RAD51-mediated pairing | Classifying HR proficiency |
| Chromatin recruitment imaging | Recruitment to damaged chromatin | Mapping structural determinants |
| Joint molecule resolution assay | Processing of recombination intermediates | Studying BRCA1-BARD1 and BLM coordination |
| Ubiquitin ligase assay | E3 ligase activity | Testing complex integrity and variants |
| CRISPR variant knock-in | Function of specific alleles | Variant classification and mechanism |
| RNA-associated HR assay | Pre-ribosomal RNA-dependent HR | Exploring RNA-linked repair |
DNA repair assays
Homologous recombination and DNA end resection assays are used to measure the functional impact of BRCA1-BARD1 perturbations. These assays typically quantify repair efficiency and resection tract formation in isogenic cell models.
RAD51 foci and pairing assays
RAD51-mediated homologous DNA pairing can be assessed by foci formation and biochemical pairing assays to determine whether BRCA1-BARD1 function is intact. These readouts are widely used to classify HR proficiency.
Structural and chromatin recruitment studies
Structural biology and chromatin recruitment assays reveal how the complex engages damaged chromatin and which determinants are required. These approaches complement functional assays by defining the molecular basis of recruitment.
Joint molecule resolution assays
Assays for joint DNA molecule resolution are used to study coordination between BRCA1-BARD1 and BLM. Such experiments help define how recombination intermediates are processed.
How CRISPR Can Be Used to Study GO:0031436 BRCA1-BARD1 complex
Knockout
CRISPR knockout of BRCA1 or BARD1 is used to abolish BRCA1-BARD1 complex function and to measure the consequences for homologous recombination, DNA end resection, and RAD51-mediated pairing. Knockout models are foundational for establishing causality in DNA repair pathways.
Point Mutation
Point-mutation knock-in enables precise testing of residues required for complex assembly, recruitment, resection, and protection. Such models help distinguish loss-of-function from separation-of-function alleles.
Knock-in
Knock-in of tagged or patient-derived alleles allows tracking of the complex and functional classification of variants in an endogenous context. This approach is valuable for linking genotype to repair phenotypes.
Overexpression
Overexpression models are used to test whether increased levels of BRCA1 or BARD1 alter DNA repair balance, complex formation, or therapy response. They complement loss-of-function studies by probing dosage effects.
How EDITGENE Supports BRCA1-BARD1 complex Research
Researchers studying BRCA1-BARD1 complex-related genes often need to determine whether a candidate gene is causally involved in DNA repair, genome maintenance, or therapy response, and CRISPR-based models provide a direct way to test this.
Contact EDITGENE today to design your custom CRISPR model for BRCA1-BARD1 complex research.
Frequently Asked Questions About BRCA1-BARD1 complex
What is the BRCA1-BARD1 complex (GO:0031436)?
It is a heterodimeric complex of BRCA1 and BARD1 that possesses ubiquitin ligase activity and is involved in genome maintenance, possibly by functioning in surveillance for DNA damage.
What genes are involved in the BRCA1-BARD1 complex?
The core genes are BRCA1 and BARD1, with functional connections to RAD51, BLM, and other DNA repair factors.
What does the BRCA1-BARD1 complex do in DNA repair?
It promotes homologous recombination by enabling DNA end resection, protecting resected ends, and stimulating RAD51-mediated DNA pairing.
How is the BRCA1-BARD1 complex recruited to damaged chromatin?
Structural determinants in the complex recognize damage-associated chromatin features to recruit it to lesions.
Why is the BRCA1-BARD1 complex important in cancer?
Its dysfunction is linked to hereditary breast and ovarian cancer and to homologous recombination deficiency that affects therapy response.
Does the BRCA1-BARD1 complex have ubiquitin ligase activity?
Yes, the heterodimer possesses ubiquitin E3 ligase activity that contributes to genome maintenance.
How does BRCA1-BARD1 coordinate with BLM?
It coordinates with BLM in complementary mechanisms of joint DNA molecule resolution.
Can BRCA1-BARD1 recognize RNA?
Yes, the complex recognizes pre-ribosomal RNA to facilitate homologous recombination.
What experimental models are used to study BRCA1-BARD1?
CRISPR knockout, point-mutation, knock-in, and overexpression models, together with repair and imaging assays, are commonly used.
What methods measure BRCA1-BARD1 function?
HR reporter assays, DNA end resection assays, RAD51 foci imaging, chromatin recruitment imaging, and joint molecule resolution assays are used.
Conclusion
GO:0031436 (BRCA1-BARD1 complex) defines a heterodimeric, ubiquitin ligase-competent tumor suppressor module that is central to genome maintenance and homologous recombination. Its roles in DNA end resection, RAD51-mediated pairing, chromatin recruitment, and joint molecule resolution make it a key subject in DNA repair and cancer research. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with repair and imaging assays, provide the experimental framework needed to dissect its mechanism and variant effects. As the field continues to uncover RNA-associated and replication-linked functions of the complex, functional genomics approaches will remain essential for translating mechanistic insights into clinical and therapeutic applications.
References
- 1. Tarsounas M et al.. 2020. The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.. Nat Rev Mol Cell Biol 21(5):284-299 PMID: 32094664
- 2. Wu D et al.. 2023. The BRCA1/BARD1 complex recognizes pre-ribosomal RNA to facilitate homologous recombination.. Cell Discov 9(1):99 PMID: 37789001
- 3. Salunkhe S et al.. 2024. Promotion of DNA end resection by BRCA1-BARD1 in homologous recombination.. Nature 634(8033):482-491 PMID: 39261729
- 4. Ceppi I et al.. 2024. Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection.. Nature 634(8033):492-500 PMID: 39261728
- 5. Zhao W et al.. 2017. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.. Nature 550(7676):360-365 PMID: 28976962
- 6. Dai L et al.. 2021. Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin.. Mol Cell 81(13):2765-2777.e6 PMID: 34102105
- 7. Tsukada K et al.. 2024. BLM and BRCA1-BARD1 coordinate complementary mechanisms of joint DNA molecule resolution.. Mol Cell 84(4):640-658.e10 PMID: 38266639
- 8. Baer R et al.. 2002. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.. Curr Opin Genet Dev 12(1):86-91 PMID: 11790560
